Flucytosine

證據等級: L5

預測適應症: 1 個

Flucytosine: From Antifungal Treatment to Bone Paget Disease

One-Sentence Summary

Flucytosine (5-fluorocytosine) is an antifungal agent conventionally used for systemic fungal infections such as cryptococcal meningitis and invasive candidiasis. The TxGNN model assigns it a high prediction score (99.04%) for Bone Paget Disease, yet this is supported by zero clinical trials and zero publications — a classic high-score, zero-evidence pattern arising from graph-walk artifacts in the knowledge graph rather than true biological signal.

Quick Overview

Item	Content
Original Indication	Systemic fungal infections (cryptococcosis, candidiasis)
Predicted New Indication	Bone Paget Disease
TxGNN Prediction Score	99.04%
Evidence Level	L5
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Flucytosine exerts its antifungal effect through a highly selective, fungus-specific mechanism: it is taken up by fungal cells via cytosine permease and converted intracellularly by fungal cytosine deaminase into 5-fluorouracil (5-FU). 5-FU then inhibits thymidylate synthase and disrupts RNA synthesis, ultimately blocking fungal nucleic acid metabolism. Critically, human cells do not express cytosine deaminase under normal physiological conditions, so this conversion — and the resulting pharmacological effect — does not occur in human tissues.

Bone Paget Disease operates through an entirely different set of pathological mechanisms: osteoclast hyperactivation, RANKL/OPG signalling imbalance, aberrant NF-κB pathway activity, SQSTM1 (p62) gene mutations, and a postulated association with paramyxovirus (measles virus nucleocapsid protein) infection. None of these pathways intersect with flucytosine’s known pharmacology.

The TxGNN model’s high score (0.9904) most likely reflects an indirect graph-path connection through pyrimidine-metabolism nodes in the knowledge graph — a graph-walk artifact rather than a genuine biological signal. This is a prototypical “High-Score, Zero-Evidence” candidate and should not be interpreted as evidence of therapeutic potential in Paget disease.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Philippines Market Information

Flucytosine is not currently marketed in the Philippines. No drug registrations or authorization numbers are on record with the FDA Philippines.

Safety Considerations

Please refer to the package insert for safety information.

Note: No TFDA/FDA Philippines package insert data, contraindication records, or drug–drug interaction data were retrievable in this evidence pack. Before any clinical consideration, full prescribing information (including known risks of bone marrow suppression and hepatotoxicity associated with flucytosine) must be reviewed from the originator’s current label.

Conclusion and Next Steps

Decision: Hold

Rationale: There is no mechanistic, clinical, or published evidence connecting flucytosine to bone Paget disease; the high TxGNN score is attributable to a knowledge-graph topology artifact (indirect pyrimidine-node linkage) rather than any real pharmacological activity in osteoclast or bone remodelling pathways. Proceeding with this candidate would not be scientifically justifiable at this stage.

To revisit this candidate, the following would be needed:

Identification of a credible mechanistic hypothesis linking flucytosine (or its metabolites) to osteoclast biology, RANKL/OPG signalling, or NF-κB pathway modulation
At least one published preclinical study (in vitro or in vivo bone model) demonstrating relevant activity
Clarification of whether the KG link is a known false-positive pattern and documentation in the model’s artifact registry
If a hypothesis emerges: a formal safety review using the complete flucytosine prescribing information (myelosuppression, hepatotoxicity, renal dosing adjustments) before any experimental design is considered
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.